134 related articles for article (PubMed ID: 1332483)
1. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years.
Domagala W; Striker G; Szadowska A; Dukowicz A; Weber K; Osborn M
Am J Pathol; 1992 Nov; 141(5):1003-12. PubMed ID: 1332483
[TBL] [Abstract][Full Text] [Related]
2. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.
Domagala W; Lasota J; Dukowicz A; Markiewski M; Striker G; Weber K; Osborn M
Am J Pathol; 1990 Dec; 137(6):1299-304. PubMed ID: 1701960
[TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
4. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
5. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma.
Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G
Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
Bedner E; Harezga B; Osborn M; Domagała W
Pol J Pathol; 1995; 46(1):11-5. PubMed ID: 7780691
[TBL] [Abstract][Full Text] [Related]
8. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
9. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.
Domagala W; Woźniak L; Lasota J; Weber K; Osborn M
Am J Pathol; 1990 Nov; 137(5):1059-64. PubMed ID: 2173410
[TBL] [Abstract][Full Text] [Related]
10. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cathepsin-D expression in female breast cancer.
Aaltonen M; Lipponen P; Kosma VM; Aaltomaa S; Syrjänen K
Anticancer Res; 1995; 15(3):1033-7. PubMed ID: 7645922
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
[TBL] [Abstract][Full Text] [Related]
13. Tumour epidermal growth factor receptor, erbB-2 and cathepsin D in node-negative invasive breast cancer: their impact on the selection of patients for systemic adjuvant therapy.
Tonkin KS; McKay JW; Stitt LW; Tokmakejian S; Haines DS
Cancer Prev Control; 1999 Apr; 3(2):131-6. PubMed ID: 10474760
[TBL] [Abstract][Full Text] [Related]
14. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
Bussen S; Rempen A; Caffier H
Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
[TBL] [Abstract][Full Text] [Related]
16. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.
Thorpe SM; Rochefort H; Garcia M; Freiss G; Christensen IJ; Khalaf S; Paolucci F; Pau B; Rasmussen BB; Rose C
Cancer Res; 1989 Nov; 49(21):6008-14. PubMed ID: 2790815
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study.
Kristensen GB; Holm R; Abeler VM; Tropé CG
Cancer; 1996 Aug; 78(3):433-40. PubMed ID: 8697388
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma.
MacConmara M; O'Hanlon DM; Kiely MJ; Connolly Y; Jeffers M; Keane FB
Int J Oncol; 2002 Apr; 20(4):717-21. PubMed ID: 11894115
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
